Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Immix Biopharma, a Nasdaq-listed company focused on relapsed/refractory AL Amyloidosis treatments, announced participation at the Jefferies Global Healthcare Conference in June 2026. The company will hold investor meetings and provide updates on its lead CAR-T cell therapy candidate, NXC-201, which has received FDA Breakthrough Therapy and RMAT des…